Date: 08 Jan 2013
Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
National Osteoporosis Foundation: America’s bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC. 2002. http://www.nof.org/
Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRef
Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142:1243–51.PubMed
FDA. Update of safety review follow-up to the October 1, 2007 ‘Early Communication about the Ongoing Safety Review of Bisphosphonates’. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm
• Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761–71. This was a secondary analysis of 3 RCTs showing that atypical fractures were a rare occurrence and were not associated with use of bisphosphonates. PubMedCrossRef
FDA. Bisphosphonates (Osteoporosis drugs): label change—atypical fractures update. Fosamax, Fosamax Plus D, Actonel, Actonel with calcium, Boniva, Atelvia, and Reclast. October 13, 2010. http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm
Gibaldi M, Perrier D. Clinical pharmacology of alendronate sodium. In: Gibaldi M, Perrier D, editors. Pharmacokinetics. New York: Marcel Dekker; 1982. p. 145–98.
NCT01406613: resolution of effect of bisphosphonates on bone in postmenopausal osteoporosis. Available at: www.Clinicaltrials.gov. Accessed November, 2012.
The Endocrine Society recommends patient-centered approach to long-term bisphosphonate use for the treatment of osteoporosis: a review of the May 2012 FDA Analysis. 2012. http://www.endo-society.org/advocacy/policy/upload/Society-Statement-on-Bisphosphonate-Use-for-Treatmentof-Osteoporosis.pdf
Bieglmayer C, Dimai HP, Gasser RW, et al. Biomarkers of bone turnover in diagnosis and therapy of osteoporosis : a consensus advice from an Austrian working group. Wiener Medizinische Wochenschrift. 2012;162:464–77.
Baxter I, Rogers A, Eastell R, et al. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporosis International. 2012. doi:10.1007/s00198-012-2097-4
• Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37. These are current endocrine guidelines on management of osteoporosis..PubMed
- Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
Current Osteoporosis Reports
Volume 11, Issue 1 , pp 45-51
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Drug holiday
- Atypical fracture
- Industry Sectors